Skip to main content
. 2020 Jan 14;10:1278. doi: 10.3389/fgene.2019.01278

Figure 4.

Figure 4

Combination chemotherapy of cisplatin with anti-miR-221/222 in suppression of tumor growth in vivo. (A) Schematic representation of the procedure for combination of cisplatin with anti-miR-221/222 in treatment of TNBC tumor burden mice developed by transplantation of MDA-MB-231 cells to the fat pad of the fourth mammary gland of nude mice. (B) Tumor growth curves after treatment with cisplatin or cisplatin +anti-miR-221/222, compared to control group treated with PBS and anti-miR NC. (C) Images of tumors from the three groups of mice. (D) Average weight of the tumors in the three groups of mice. (E) Expression levels of miR-221 and miR-222 in tumors from the three groups of mice. Values are equal to mean ± SEM (n = 10). *p < 0.05, **p < 0.01.